Are China’s Healthcare and Biopharma Sectors Really Open for Investment?
By Patrick Beyrer
To attract foreign investment, the Chinese healthcare and biopharma sectors are more open for business than ever – or at least they claim to be. But challenges exist beneath the surface.
COVID-19 Is Reshaping Global Pharmaceutical Competition – to Asia’s Benefit
By Hannah Elyse Sworn
The valuable experience gained by Asian companies during the pandemic could upset the West’s monopoly in high-value drugs more generally, with implications for global access to medicines.
As China Rolled Out Its COVID-19 Shots, Victims of Earlier Vaccine Scandals Vanished
By Renee Xia
China’s habit of disappearing and censoring critics is not the way to win trust in its vaccine industry.
The Politics Behind China’s COVID-19 Vaccine Choices
By Bonnie Girard
China is keeping its vaccination campaign homegrown -- despite some reservations from the public.
China Prepares for Big Pharma
By Zachary Torrey
Pharmaceuticals is a target industry under the “Made in China 2025” plan.
Why China Could be a Game Changer for Global Health
By Charlotte Röhren
With its growing international integration, China is becoming a major actor in global health issues.
Chinese Consumers Will Change the Global Economy
By Matthias Lomas
As China's massive population begins to spend more, the world will take notice.
China Celebrates Its First Nobel Prize in the Sciences
By Shannon Tiezzi
The winner, Tu Youyou, fused herbal research and biochemistry to develop a new anti-malaria drug.
Ali Health: A Revolution for China’s Healthcare Industry?
By Ariella Rotenberg and Peng Di
Led by Alibaba, private-sector players are threatening a major shakeup of China’s healthcare sector.
Has China Found the Cure for Ebola?
By Shannon Tiezzi
A Chinese pharmaceutical company is seeking to fast-track approval of an experimental cure for Ebola.